Literature DB >> 31689503

How the central domain of dystrophin acts to bridge F-actin to sarcolemmal lipids.

Dominique Mias-Lucquin1, Raphael Dos Santos Morais2, Angélique Chéron1, Mélanie Lagarrigue3, Steve J Winder4, Thomas Chenuel1, Javier Pérez5, Marie-Sousai Appavou6, Anne Martel7, Guillaume Alviset1, Elisabeth Le Rumeur1, Sophie Combet8, Jean-François Hubert1, Olivier Delalande9.   

Abstract

Dystrophin is a large intracellular protein that prevents sarcolemmal ruptures by providing a mechanical link between the intracellular actin cytoskeleton and the transmembrane dystroglycan complex. Dystrophin deficiency leads to the severe muscle wasting disease Duchenne Muscular Dystrophy and the milder allelic variant, Becker Muscular Dystrophy (DMD and BMD). Previous work has shown that concomitant interaction of the actin binding domain 2 (ABD2) comprising spectrin like repeats 11 to 15 (R11-15) of the central domain of dystrophin, with both actin and membrane lipids, can greatly increase membrane stiffness. Based on a combination of SAXS and SANS measurements, mass spectrometry analysis of cross-linked complexes and interactive low-resolution simulations, we explored in vitro the molecular properties of dystrophin that allow the formation of ABD2-F-actin and ABD2-membrane model complexes. In dystrophin we identified two subdomains interacting with F-actin, one located in R11 and a neighbouring region in R12 and another one in R15, while a single lipid binding domain was identified at the C-terminal end of R12. Relative orientations of the dystrophin central domain with F-actin and a membrane model were obtained from docking simulation under experimental constraints. SAXS-based models were then built for an extended central subdomain from R4 to R19, including ABD2. Overall results are compatible with a potential F-actin/dystrophin/membrane lipids ternary complex. Our description of this selected part of the dystrophin associated complex bridging muscle cell membrane and cytoskeleton opens the way to a better understanding of how cell muscle scaffolding is maintained through this essential protein.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bicelle membrane model; Dystrophin; F-actin; Mass spectrometry; Molecular modelling; Small-angle scattering

Mesh:

Substances:

Year:  2019        PMID: 31689503     DOI: 10.1016/j.jsb.2019.107411

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  6 in total

Review 1.  CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Cedric Happi Mbakam; Gabriel Lamothe; Guillaume Tremblay; Jacques P Tremblay
Journal:  Neurotherapeutics       Date:  2022-02-14       Impact factor: 6.088

2.  Using CRISPR/Cas9 System to Knock out Exon 48 in DMD Gene.

Authors:  Mahintaj Dara; Vahid Razban; Mahdieh Talebzadeh; Sepideh Moradi; Mehdi Dianatpour
Journal:  Avicenna J Med Biotechnol       Date:  2021 Apr-Jun

Review 3.  Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update.

Authors:  Chengmei Sun; Luoan Shen; Zheng Zhang; Xin Xie
Journal:  Genes (Basel)       Date:  2020-07-23       Impact factor: 4.096

Review 4.  Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy.

Authors:  Cedric Happi Mbakam; Gabriel Lamothe; Jacques P Tremblay
Journal:  Front Med (Lausanne)       Date:  2022-03-28

5.  Theragnosis for Duchenne Muscular Dystrophy.

Authors:  Leonela Luce; Micaela Carcione; Chiara Mazzanti; Paula I Buonfiglio; Viviana Dalamón; Lilia Mesa; Alberto Dubrovsky; José Corderí; Florencia Giliberto
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

6.  Effects of Mini-Dystrophin on Dystrophin-Deficient, Human Skeletal Muscle-Derived Cells.

Authors:  Jinhong Meng; John Counsell; Jennifer E Morgan
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.